Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke · 2024
Central hypothyroidism caused by roxadustat.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hauge Jostein Wågen, Wærp Cora Mjeldheim, Hofsø Dag, Abedini Sadollah
Аннотация
BACKGROUND: Isolated central hypothyroidism, although rare, has been documented in case reports in patients with chronic kidney disease (CKD) treated with roxadustat, a novel agent in the treatment of renal anaemia.
CASE PRESENTATION: A woman in her sixties with CKD stage 5 (not in dialysis) and no prior thyroid disease, was started on treatment with roxadustat 70 mg x 3 weekly for renal anaemia. During treatment, the patient developed classic signs of hypothyroidism (fatigue, dry skin, constipation, difficulty concentrating), with blood samples consistent with isolated central hypothyroidism. Roxadustat was discontinued awaiting further investigation. One month later the patient's symptoms had resolved, and six weeks later thyroid hormones had normalised. The patient was subsequently started on a regular erythropoiesis-stimulating agent.
INTERPRETATION: This example highlights the importance of routine monitoring of thyroid function in patients with CKD receiving roxadustat. Importantly, the condition resolved upon discontinuation of the medication.
CASE PRESENTATION: A woman in her sixties with CKD stage 5 (not in dialysis) and no prior thyroid disease, was started on treatment with roxadustat 70 mg x 3 weekly for renal anaemia. During treatment, the patient developed classic signs of hypothyroidism (fatigue, dry skin, constipation, difficulty concentrating), with blood samples consistent with isolated central hypothyroidism. Roxadustat was discontinued awaiting further investigation. One month later the patient's symptoms had resolved, and six weeks later thyroid hormones had normalised. The patient was subsequently started on a regular erythropoiesis-stimulating agent.
INTERPRETATION: This example highlights the importance of routine monitoring of thyroid function in patients with CKD receiving roxadustat. Importantly, the condition resolved upon discontinuation of the medication.